Enroll now to receive emails and resources designed to help patients,
caregivers, and information seekers throughout the DUPIXENT
treatment journey.
Message
Are you sure you want to leave?
Please note: By clicking on this link, you will be leaving this Sanofi-hosted US website and going to another, entirely independent website. Sanofi US and Regeneron provide these links as a service to their website visitors and users; however, they take no responsibility for the information on any website but their own.
Are you sure you want to leave?
Please note: By clicking on this link, you will be leaving this Sanofi-hosted US website and going to another, entirely independent website. Sanofi US and Regeneron provide these links as a service to their website visitors and users; however, they take no responsibility for the information on any website but their own.
This DUPIXENT® (dupilumab)
website is for U.S. healthcare
professionals only. Click
"continue"
only if you are a U.S.
healthcare professional.
US-DAS-1231(1)
Estás a punto de abandonar este sitio para visitar nuestro sitio en inglés. Haz clic en "Continuar" si quieres proseguir.
US-DAS-1231(1)
Success!
Your email is on its way. Be sure to check your inbox.